Company / Cost of Revenue
Neogen Cost of Revenue History
FY2016-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$473.3M
FY2024
5-year range
$284.1M / $473.3M
FY2020-FY2024
Trend
+2.8%
vs FY2023
Sector context
#60 of 107
Health Care
What the data says
At $473M, Neogen's cost of revenue ranks #48 of 107 in the Health Care sector. Cost of Revenue has increased for 5 consecutive years, from $222M in FY2019 to $473M in FY2024.
Based on SEC 10-K filings.
$473M in FY2024 with a 5-year CAGR of +16.4%.
Increased from $416M to $473M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +18.5%
- 5-Year CAGR
- +16.4%
- 10-Year CAGR
- -
Sector benchmark
#48 of 107 in Health CareTop 44% of 107This company $473.3M Sector average $11.8B
▼
-96.0% below sector average
Key checks
Key Insights
- Neogen's cost of revenue has grown for 5 consecutive years.
- 5-year CAGR of +16.4%, indicating consistent growth.
- In FY2024, cost of revenue increased 2.8% year-over-year.
- Ranks #60 out of 107 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 0/9 (multiple financial health concerns)
- Altman Z-Score 0.59 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | $473.3M | +2.8% |
| FY2023 | $460.3M | +10.5% |
| FY2022 | $416.5M | +46.6% |
| FY2021 | $284.1M | +12.1% |
| FY2020 | $253.4M | +14.2% |
| FY2019 | $221.9M | -0.2% |
| FY2018 | $222.3M | +5.0% |
| FY2017 | $211.7M | +11.8% |
| FY2016 | $189.4M | +12.6% |
As of FY2024 · SEC 10-K · Updated Mar 28, 2026